Skip to content

Study · Animal study (in vivo) · mouse · 2009

4 results

A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.

Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC

Journal of controlled release : official journal of the Controlled Release Society21 Oct 2008Cited by 55 (Europe PMC)

PMID18977255 (opens in a new tab)DOI10.1016/j.jconrel.2008.09.091 (opens in a new tab)PepBankPUB-18977255
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, oral native exendin‑4 increased mean total hypoglycemic degree by 8.8+/-7.3%.

    In plain wordsIn mice, oral native exendin‑4 increased the total hypoglycemic degree by 8.8+/-7.3%.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseTotal hypoglycemic degree
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 microg/mouse · oralAs given in this study (mouse).

    Measurements

    Mean total hypoglycemic degree increase
    8.8%
    native exendin-4, 1 microg/mouse

    Source sentences

    Summary
    whereas 1 microg/mouse of native exendin-4 showed an increase of 8.8+/-7.3%.
    1 context sentence
    Summary · context
    The hypoglycemic effects and pharmacokinetics of these analogues after oral administration were evaluated in db/db mice and Sprague-Dawley rats, respectively.
  2. 02LabEx vivo tissueActivity measurement

    In isolated rat islets, native exendin‑4 had insulin secretion potency comparable to the biotinylated analogues.

    In plain wordsIn lab tests on rat islets, native exendin‑4 and biotinylated analogues had comparable insulin secretion potency.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInsulin secretion potency
    Study

    ratn: not reported in source

    Isolated rat islets
    Comparator
    Biotinylated exendin-4 analogues
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These biotinylated exendin-4 analogues preserved GLP-1 receptor binding affinity and stimulated insulin secretion in RIN-m5F murine insulinoma cells and in isolated rat islets, respectively, and were as potent as exendin-4.
  3. 03LabIn vitro (cells)Activity measurement

    In RIN-m5F murine insulinoma cells, native exendin‑4 had GLP-1 receptor binding potency comparable to the biotinylated analogues.

    In plain wordsIn cells from mice, native exendin‑4 and biotinylated analogues had comparable receptor-binding potency.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGLP-1 receptor binding affinity
    Study

    mousen: not reported in source

    RIN-m5F murine insulinoma cells
    Comparator
    Biotinylated exendin-4 analogues
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These biotinylated exendin-4 analogues preserved GLP-1 receptor binding affinity and stimulated insulin secretion in RIN-m5F murine insulinoma cells and in isolated rat islets, respectively, and were as potent as exendin-4.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 04LabNot a test of Exenatide (exendin-4) aloneIn vitro (cell-free)Activity measurement

    In rat intestinal fluid, native exendin‑4 had lower stability than DB-Ex-4, whose stability was 9.0-fold better.

    In plain wordsIn lab tests with rat intestinal fluid, native exendin‑4 was less stable than DB-Ex-4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseStability in intestinal fluid
    Study

    ratn: not reported in source

    Rat intestinal fluid
    Comparator
    DB-Ex-4
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    In particular, DB-Ex-4 showed 9.0-fold better stability against rat intestinal fluid than exendin-4.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.